Chronic lymphocytic leukemia treatment algorithm 2018

Chronic lymphocytic leukemia, biology, new diagnosis and treatment: review article

Chronic lymphocytic leukemia (CLL) is a malignancy of B CD5+cells and is the most common type of leukemia in adults. The disease is more common in men over 50 years in western countries. CLL is associated with defective apoptosis in B cells. CLL was traditionally regarded as a disease that occurs before naïve B cells meet the antigen in the lymph nodes. Laboratory diagnosis requires white blood...

CHRONIC LYMPHOCYTIC LEUKEMIA Treatment algorithms in CLL

CLL therapy has changed dramatically over the last few years. This development has been aided by progress in 2 areas: (1) a better understanding of CLL biology (and with it discovery and characterization of new prognostic markers); and (2) emergence of novel agents. The combined impact of advances in these areas is leading to new concepts and approaches in CLL therapy. Treatment of CLL has been...

Biology and treatment of chronic lymphocytic leukemia.

Major advances have occurred in our understanding of the biology, immunology, and opportunities for treatment of chronic lymphocytic leukemia (CLL) in recent times. Surface antigen analysis has helped us define classical CLL and differentiate it from variants such as marginal zone leukemia, mantle cell leukemia, and prolymphocytic leukemia. An important observation has been that the B-cells in ...

Targeted treatment for chronic lymphocytic leukemia

The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/cyclophosphamide/rituximab combination has demonstrated surviva...

New target of chronic lymphocytic leukemia treatment.